A rising tide scenario: Why other Big Pharmas could follow Lilly into psychedelics on July 20, 2026 AbbVie AtaiBeckley Big Pharma BPL-003 Eli Eli Lilly Hallucinogens mental health neuroplastogens regulatory easing treatment-resistant depression +
Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley on July 17, 2026 acquisition AtaiBeckley BPL-003 Eli Glucagon-Like Peptide 1 Hallucinogens mental health Phase 3 treatment-resistant depression upfront +
Spring Health Acquires Alma to Expand Insurance Reach in Virtual Mental Health on February 03, 2026 2026 acquisition Alma Insurance mental health Spring Health virtual care +
No Recent News on BetterHelp's Quiet AI Expansion on January 20, 2026 acquisition BetterHelp expansion Insurance mental health Revenue Decline Teladoc +
Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact on October 28, 2025 Clearmind Medicine Clinical Trials governmental engagement Mary-Elizabeth mental health partnerships psychedelic medicine regulatory advocacy U.S. +
AbbVie Buys Gilgamesh's Psychedelic Drug Bretisilocin for $1.2B on August 26, 2025 AbbVie Acquisition bretisilocin Dosage Forms Gilgamesh GM-2505 Hallucinogens mental health Neuroscience discipline +
CDC Launches 'Free Mind' Campaign Targeting Teen Substance Use and Mental Health on August 08, 2025 Adolescence Alcohol or Other Drugs use Centers for Disease Control and Prevention (U.S.) Drug Overdose fentanyl Free Mind ' Campaign mental health Strategy teen suicide +
Newleos Therapeutics Launches with $93.5M to Advance Novel Neuropsychiatric Treatments on February 14, 2025 Anxiety Disorders assets Funding GABA Modulators mental health Neuropsychiatry Newleos Roche (company) Series Substance Use Disorders +